Akoya Biosciences Announces 2024 Financial Results Amid Revenue Decline Akoya Biosciences reported a 15.5% revenue decline in 2024, totaling $81.7 million. Despite challenges, gross margins improved to 58.6%, reflecting operational efficiencies. The company’s operating loss narrowed to $46.7 million, down from $57.7 million in 2023. Key developments include a planned merger with Quanterix and growth in spatial phenotyping solutions.12